Trump announces reforms to accelerate access to psychedelic drug treatments

President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelic drugs like ibogaine, which U.S. military veteran groups claim can treat post-traumatic stress disorder (PTSD). The reform aims to accelerate access to medical research and treatment involving psychedelic substances.